Paolo Maione
Avellino, 83100, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 64 publications
Correction: Maione et al. Amivantamab Plus Lazertinib and Platin-Based Chemotherapy Plus Osimertinib in EGFR-Mutant NSCLC: How to Choose Among Them and When Is Monotherapy with Osimertinib Still the Best Option? Curr. Oncol. 2026, 33, 54.
Journal: Current oncology (Toronto, Ont.)
Published: June 25, 2026
Amivantamab Plus Lazertinib and Platin-Based Chemotherapy Plus Osimertinib in EGFR-Mutant NSCLC: How to Choose Among Them and When Is Monotherapy with Osimertinib Still the Best Option?
Journal: Current oncology (Toronto, Ont.)
Published: December 01, 2025
Lorlatinib and Amivantamab: A Paradigm Shift in EGFR and ALK Positive NSCLC, with More Effective but More Toxic Treatments Requiring a Well-Structured Shared Decision Making.
Journal: Oncology research
Published: September 08, 2025
New Treatment Strategies in Advanced Epidermal Growth Factor Receptor-Driven Non-Small Cell Lung Cancer: Beyond Single Agent Osimertinib.
Journal: Cancers
Published: January 15, 2025
Targeting ALK receptors in non-small cell lung cancer: what is the road ahead?
Journal: Expert opinion on therapeutic targets
Published: August 20, 2024
The Role of Adjuvant Chemotherapy before Osimertinib in Epidermal Growth Factor Receptor Mutant Resected Non-Small Cell Lung Cancer and Communicating It to Patients.
Journal: Current oncology (Toronto, Ont.)
Published: December 23, 2023
Neutrophil-to-Lymphocyte Ratio Is a Major Prognostic Factor in Non-small Cell Lung Carcinoma Patients Undergoing First Line Immunotherapy With Pembrolizumab.
Journal: Cancer diagnosis & prognosis
Published: October 10, 2022
Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy.
Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy.
Journal: International journal of molecular sciences
Published: June 30, 2022
New approach to implement cancer patient care: The valutazione percorso rete oncologica campana (ValPeROC)-experience from an Italian oncology network.
Journal: European journal of cancer care
Published: March 08, 2022
Chemotherapy plus single/double immunotherapy in the treatment of non-oncogene addicted advanced non-small cell lung cancer: where do we stand and where are we going?
Journal: Expert review of anticancer therapy
Published: January 06, 2022
The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target-a narrative review.
Journal: Translational lung cancer research
Published: November 29, 2021
Last Updated: 09/26/2026